EUVIMEDEUVIMED entdecken
Crossref

Virological and Antifibrotic Efficacy of Antiviral Treatment for Hepatitis В+C in HIV-positive Patients

Mariana Prokopovych, Ihor Hryzhak

Wiadomości Lekarskie · 2025

DOI: 10.36740/wlek/210024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Wiadomości Lekarskie, 2025. Verfasst von Mariana Prokopovych und 1 weiteren Autor:innen. Beteiligte Einrichtung: IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE. Hauptthemen laut MEDLINE: Antiviral Agents, HIV Infections, Coinfection, Liver Cirrhosis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To study and compare the efficacy of different regimens of combination antiviral therapy for hepatitis C and B in achieving a sustained virological response in patients with HIV/HBV/HCV coinfection and their impact on the degree of liver fibrosis. Material and methods We examined 113 HIV-infected adult patients with HBV/HCV coinfection who were registered at the Municipal Non-profit Enterprise “Infectious Diseases Center of the Ivano-Frankivsk Regional Council” between 2017 and 2019.

Results

The treatment regimens with two direct-acting antivirals (sofosbuvir/ledipasvir, sofosbuvir+daclatasvir, sofosbuvir/velpatasvir and sofosbuvir/ledipasvir and ribavirin resulted in 100 % sustained virologic response. The efficacy of the pegylated interferon, sofosbuvir, and ribavirin regimen was lower, with sustained virologic response achieved in 86.2 % of patients. The lowest efficacy was observed with the sofosbuvir and ribavirin regimen – sustained virologic response achieved in 75.0 % of patients. Primary HBV resistance to tenofovir/emtricitabine was identified in 1.76 % of patients in the entire cohort. Among patients in the group treated with combined antiviral therapy for HBV and HCV using tenofovir/emtricitabine and direct-acting antivirals with or without ribavirin, the incidence of liver fibrosis F3-F4, as assessed by point-shear wave elastography, decreased from 20 % to 2.5 % (р

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHIV InfectionsCoinfectionLiver CirrhosisHepatitis BHepatitis CHumansMaleFemaleAdultMiddle AgedSofosbuvirDrug Therapy, CombinationTreatment OutcomePyrrolidinesBenzimidazolesFluorenesValineCarbamatesImidazoles

Stichwörter der Autor:innen

hepatitis Bhepatitis Cantiviral agentshuman immunodeficiency virusliver fibrosis

Substanzen

Antiviral AgentsSofosbuvirPyrrolidinesdaclatasvirBenzimidazolesFluorenesValineCarbamatesImidazoles

Autor:innen und Institutionen

  • IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE.

Zitieren

APA

Prokopovych, M., & Hryzhak, I. (2025). Virological and Antifibrotic Efficacy of Antiviral Treatment for Hepatitis В+C in HIV-positive Patients. Wiadomości Lekarskie. https://doi.org/10.36740/wlek/210024

Vancouver

Prokopovych M, Hryzhak I. Virological and Antifibrotic Efficacy of Antiviral Treatment for Hepatitis В+C in HIV-positive Patients. Wiadomości Lekarskie. 2025. doi:10.36740/wlek/210024

BibTeX
@article{Prokopovych2025,
  author = {Prokopovych, Mariana and Hryzhak, Ihor},
  title = {Virological and Antifibrotic Efficacy of Antiviral Treatment for Hepatitis В+C in HIV-positive Patients},
  journal = {Wiadomości Lekarskie},
  year = {2025},
  doi = {10.36740/wlek/210024}
}
Kostenlos starten →